Drug
Afatinib
Afatinib: highest development phase Phase 2, developed by Boehringer Ingelheim, Exelixis. 4 trial records tracked on RxWires.
- Highest phase
- Phase 2
- Developer
- Boehringer Ingelheim, Exelixis
Trials
| Drug | Phase | Indication |
|---|---|---|
| Afatinib NCT02795156 | Phase 2 | Non-small Cell Lung Carcinoma |
| afatinib NCT01426958 | Phase 1 | Healthy |
| Afatinib NCT01836341 | Phase 1 | Non-small Cell Lung Cancer |
| Afatinib NCT01396265 | Phase 1 | Healthy |
Latest
No recent events.
Follow Afatinib on RxWires to get trial status changes, FDA actions, filings and patent dates as they happen.
Sourced from ClinicalTrials.gov, openFDA, SEC EDGAR and the FDA Orange Book. Not investment or medical advice.